With Investors' Eyes On Biotechs, Biotechs Must Keep Their Eyes On Transparency
Source: Citeline
By Darcy Grabenstein
If recent pharmaceutical mergers and acquisitions are any indication, 2019 is poised to marked by industry deal-making. Earlier this month, the J.P. Morgan Healthcare Conference coincided with Eli Lilly & Co.’s $8 billion acquisition of Loxo Oncology Inc. The news came on the heels of the $74 billion merger of Bristol-Myers Squibb and Celgene, and the $5.1 billion acquisition of Tesaro Inc. by GlaxoSmithKline PLC.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Citeline
This website uses cookies to ensure you get the best experience on our website. Learn more